143 related articles for article (PubMed ID: 32074412)
1. Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer's Disease: A Re-Analysis of the CATIE-AD Study.
Nagata T; Shinagawa S; Yoshida K; Noda Y; Shigeta M; Mimura M; Nakajima S
J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32074412
[TBL] [Abstract][Full Text] [Related]
2. Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.
Yoshida K; Roberts R; Suzuki T; Lebowitz B; Reeves S; Howard R; Abe T; Mimura M; Uchida H
Am J Geriatr Psychiatry; 2017 Jul; 25(7):708-716. PubMed ID: 28215900
[TBL] [Abstract][Full Text] [Related]
3. Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study.
Nagata T; Shinagawa S; Nakajima S; Mimura M; Shigeta M
J Alzheimers Dis; 2018; 66(1):139-148. PubMed ID: 30248052
[TBL] [Abstract][Full Text] [Related]
4. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.
Nagata T; Shinagawa S; Nakajima S; Plitman E; Mihashi Y; Hayashi S; Mimura M; Nakayama K
J Alzheimers Dis; 2016; 50(3):839-45. PubMed ID: 26836181
[TBL] [Abstract][Full Text] [Related]
5. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study.
Nagata T; Nakajima S; Shinagawa S; Plitman E; Nakayama K; Graff-Guerrero A; Mimura M
J Alzheimers Dis; 2017; 60(1):263-272. PubMed ID: 28800334
[TBL] [Abstract][Full Text] [Related]
6. Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data.
Ozawa C; Roberts R; Yoshida K; Suzuki T; Lebowitz B; Reeves S; Howard R; Abe T; Mimura M; Uchida H
J Clin Psychiatry; 2017; 78(9):e1204-e1210. PubMed ID: 29045769
[TBL] [Abstract][Full Text] [Related]
7. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
[TBL] [Abstract][Full Text] [Related]
8. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
9. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.
Mohamed S; Rosenheck R; Lyketsos CG; Kaczynski R; Sultzer DL; Schneider LS
J Clin Psychiatry; 2012 Jan; 73(1):121-8. PubMed ID: 21939611
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
Cummings JL; Nadel A; Masterman D; Cyrus PA
J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
[TBL] [Abstract][Full Text] [Related]
12. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
[TBL] [Abstract][Full Text] [Related]
13. Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development.
Burke SL; Maramaldi P; Cadet T; Kukull W
Arch Gerontol Geriatr; 2016; 65():231-8. PubMed ID: 27111252
[TBL] [Abstract][Full Text] [Related]
14. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
15. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings JL; Schneider E; Tariot PN; Graham SM;
Neurology; 2006 Jul; 67(1):57-63. PubMed ID: 16832078
[TBL] [Abstract][Full Text] [Related]
16. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease.
Furukawa K; Tomita N; Uematsu D; Okahara K; Shimada H; Ikeda M; Matsui T; Kozaki K; Fujii M; Ogawa T; Umegaki H; Urakami K; Nomura H; Kobayashi N; Nakanishi A; Washimi Y; Yonezawa H; Takahashi S; Kubota M; Wakutani Y; Ito D; Sasaki T; Matsubara E; Une K; Ishiki A; Yahagi Y; Shoji M; Sato H; Terayama Y; Kuzuya M; Araki N; Kodama M; Yamaguchi T; Arai H
Geriatr Gerontol Int; 2017 Feb; 17(2):211-218. PubMed ID: 26711658
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
18. Quantifying placebo responses in clinical evaluation of neuropsychiatric symptoms in Alzheimer's disease.
Zhang N; Lv Y; Li H; Chen J; Li Y; Yin F; Li L; Zheng Q
Eur J Clin Pharmacol; 2019 Apr; 75(4):497-509. PubMed ID: 30612155
[TBL] [Abstract][Full Text] [Related]
19. Treated Behavioral Symptoms and Mortality in Medicare Beneficiaries in Nursing Homes with Alzheimer's Disease and Related Dementias.
Huang TY; Wei YJ; Moyo P; Harris I; Lucas JA; Simoni-Wastila L
J Am Geriatr Soc; 2015 Sep; 63(9):1757-65. PubMed ID: 26310959
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
